Compare · CRMD vs OUST
CRMD vs OUST
Side-by-side comparison of CorMedix Inc. (CRMD) and Ouster Inc. (OUST): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while OUST operates in Industrials - the two are in different parts of the market.
- OUST is the larger of the two at $518.2M, about 3.3x CRMD ($155.0M).
- OUST has been more active in the news (4 items in the past 4 weeks vs 2 for CRMD).
- OUST has more recent analyst coverage (18 ratings vs 8 for CRMD).
- Company
- CorMedix Inc.
- Ouster Inc.
- Price
- -
- -
- Market cap
- $155.0M
- $518.2M
- 1M return
- -
- -18.70%
- 1Y return
- -
- -3.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 2
- 4
- Recent ratings
- 8
- 18
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Latest CRMD
- Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
- Oppenheimer initiated coverage on Cormedix with a new price target
- Director Dillione Janet converted options into 48,909 shares, increasing direct ownership by 71% to 117,835 units (SEC Form 4)
- Chief Financial Officer Blum Susan covered exercise/tax liability with 8,424 shares, decreasing direct ownership by 6% to 124,315 units (SEC Form 4)
- Chief Operating Officer Hurlburt Elizabeth covered exercise/tax liability with 8,076 shares, decreasing direct ownership by 3% to 270,463 units (SEC Form 4)
- Chief Legal Officer Zelnick Kaufman Beth covered exercise/tax liability with 8,424 shares, decreasing direct ownership by 3% to 260,684 units (SEC Form 4)
- CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
- Today's Stocks in the News
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest OUST
- Ouster Announces Date for Third Quarter 2026 Earnings Call
- SEC Form 4 filed by Ouster Inc.
- AVerMedia and Stereolabs Accelerate AI Vision Deployment with NVIDIA JetPack 7.2
- Ouster Partners with Seneca to Advance Autonomous Drone Technology for Wildfire Response Operations
- General Counsel and Secretary Chung Megan sold $389,993 worth of shares (11,484 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 189,291 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Spencer Darien sold $434,953 worth of shares (12,808 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 286,998 units (SEC Form 4) to satisfy withholding obligation
- President and CEO Pacala Charles Angus sold $1,031,847 worth of shares (30,385 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,041,816 units (SEC Form 4) (withholding tax)
- Chief Revenue Officer Jacquemet Cyrille sold $302,093 worth of shares (8,896 units at $33.96), decreasing direct ownership by 8% to 105,538 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Gianella Kenneth P. sold $532,682 worth of shares (15,686 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 245,328 units (SEC Form 4) (withholding obligation)
- Chief Technology Officer Frichtl Mark sold $637,691 worth of shares (18,778 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 318,987 units (SEC Form 4) to satisfy tax liability